Glenmark said that according to data from market research firm AIOCD AWACS, FabiFlu clocked sales of Rs 351.9 crore in April, a more than seven-fold jump from March.
The huge jump in FabiFlu sales happened owing to a surge in Covid cases during the month. Daily fresh cases touched 401,993 on April 30.
FabiFlu is an oral antiviral drug, which is prescribed to mild to moderate Covid patients who are in home quarantine.
In January, sales of FabiFlu was Rs 12.4 crore, which slipped further in February to Rs 11.6 crore. This was when Covid cases were hovering around a few thousand cases daily.
Typically, chronic therapy medicines like anti-diabetic and anti-hypertensive feature in the top five medicine brands in the pharma market.
Glenn Saldanha, managing director (MD) and chief executive officer (CEO) of Glenmark said, “We were the first to launch FabiFlu in India for the treatment of mild to moderate cases and have been enabling its access to patients across the country. We will continue to innovate and explore other promising treatment options in our core segments.”
Drugs that are used to treat Covid or used by people as immunity boosters have seen a jump in sales and, in turn, rankings.
The domestic pharmaceuticals market has seen a rebound in April, with sales growing 51.5 per cent over last year, thanks to the low base of April 2020 and a pick-up in demand for Covid-19 drugs.
When compared to the domestic sales of April 2019, the growth is around 37 per cent. However, compared to the previous month (March 2020), it is 18.4 per cent.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.